Built on Science. Validated in Practice.
Our Mission
The Clinical Case for MGrx
Clinically Proven Effective in One Treatment
Triple Therapy for Meibomian Gland Dysfunction: Microdermoabrasion, Heat, and Meibomian Gland Expression
A single MGrx treatment session produced statistically significant improvements in OSDI symptom scores and NIKBUT tear film stability. Patients demonstrated measurable relief from evaporative dry eye disease after one in-office visit.
Read the Full StudyMeibomian Gland Dysfunction Treated with a Novel Device: A Case Series
A case series evaluating MGrx in patients with MGD demonstrated consistent improvements in meibomian gland function and patient-reported dry eye symptoms following a single treatment session.
Read the Full StudyClinical Outcomes of Combined Thermal and Mechanical Therapy for Evaporative Dry Eye
Objective measures of tear film stability and meibomian gland expressibility showed statistically significant improvement following a single MGrx treatment, with patient-reported outcomes confirming sustained symptom relief.
Read the Full StudyTriple Therapy for Meibomian Gland Dysfunction with a Single Device: A Pilot Study
31 patients showed a 37% decrease in OSDI score, 44% increase in aNIKBUT, and 24% increase in iNIKBUT after a single MGrx session. All results were statistically significant (p ≤ 0.002), confirming rapid, objective improvement in tear film stability.
Read the Full StudyThe Technology
Tri-Modal Treatment
MGrx delivers three therapeutic actions in a single session: Thermal Exfoliation gently removes debris and biofilm from the lid margin; Massage softens and mobilizes inspissated meibum within the glands; and Expression clears obstructed glands to restore healthy lipid secretion — all in one atraumatic pass.
Painless Atraumatic Expression
Simultaneous application of controlled heat and gentle mechanical expression addresses both the thermal and physical components of meibomian gland obstruction — the same mechanism validated in peer-reviewed literature.
Built-In Dry Eye Diagnostic
The MGrx features an integrated touchscreen patient survey that administers validated dry eye questionnaires — including OSDI — directly on the device before and after treatment. Results are captured automatically, giving clinicians objective before-and-after data at the point of care without additional software or manual entry.
FDA Registered & Clinically Validated
MGrx is FDA registered and has undergone rigorous clinical validation. Our device meets the safety and efficacy standards required for use in licensed eye care practices across the United States.
Clinical Advisory Team
Dr. Rebecca Holloway
OD, FAAO, Dipl. ABO
Chief Clinical Advisor
Dr. Holloway brings over 18 years of specialty dry eye practice experience. She has published extensively on meibomian gland dysfunction and serves on the editorial board of the Ocular Surface journal.
Dr. Marcus Chen
MD, PhD
Research Director
Dr. Chen leads MGrx's clinical research program. His laboratory work on lipid layer dynamics and thermal therapy mechanisms formed the scientific foundation for the device's treatment protocol.
Dr. Anita Patel
OD, FSLS, FAAO
Clinical Education Lead
Dr. Patel oversees provider training and clinical onboarding. She has trained over 300 eye care professionals in advanced dry eye management and specialty contact lens fitting.